CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index; 9 of the 17 sources its claims cite were checked for support.
Abstract
BACKGROUND: . METHODS: After conducting preclinical in vitro and in vivo studies, we evaluated the safety and pharmacodynamic effects of single escalating doses of NTLA-2001 in six patients with hereditary ATTR amyloidosis with polyneuropathy, three in each of the two initial dose groups (0.1 mg per kilogram and 0.3 mg per kilogram), within an ongoing phase 1 clinical study. RESULTS: after a single dose. Serial assessments of safety during the first 28 days after infusion in patients revealed few adverse events, and those that did occur were mild in grade. Dose-dependent pharmacodynamic effects were observed. At day 28, the mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the group that received a dose of 0.1 mg per kilogram and was 87% (range, 80 to 96) in the group that received a dose of 0.3 mg per kilogram. CONCLUSIONS: . (Funded by Intellia Therapeutics and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT04601051.).
Overview
CoChat Summary
TL;DR
In six patients with hereditary ATTR amyloidosis with polyneuropathy, single intravenous doses of NTLA-2001, a CRISPR-Cas9 lipid nanoparticle therapy, produced dose-dependent reductions in serum TTR protein at day 28 and only mild adverse events. This interim phase 1 study provides early clinical proof of concept for in vivo CRISPR-Cas9 gene editing.
Key findings
- At day 28, mean reduction from baseline in serum TTR protein concentration was 52% (range, 47 to 56) in the 0.1 mg/kg group and 87% (range, 80 to 96) in the 0.3 mg/kg group.
- Adverse events occurred in three of six patients and were all grade 1 (mild); no serious adverse events were observed. One patient had a grade 1 infusion-related reaction, and increased d-dimer levels in five of six patients returned to baseline by day 7.
- Preclinical studies showed durable TTR knockout after a single dose: in primary human hepatocytes, NTLA-2001 had EC50 0.05 to 0.15 nmol/L and EC90 0.17 to 0.67 nmol/L, with ≥93.7% TTR editing and ≥95% reduction in TTR protein production; in cynomolgus monkeys, a single dose of Cyn-LNP at 3 or 6 mg/kg produced maximum whole-liver gene editing of 73% and >94% reduction in serum TTR protein sustained over 12 months.
Methods
- Interim results from two initial dose groups of a two-part, global, phase 1, open-label, multicenter study: six patients with hereditary ATTR amyloidosis with polyneuropathy received a single intravenous dose of NTLA-2001 at 0.1 mg/kg or 0.3 mg/kg (three patients each) between November 2020 and April 2021.
- Key eligibility included age 18 to 80 years, polyneuropathy due to hATTR amyloidosis with or without cardiomyopathy, body weight 50 to 90 kg, and lack of access to approved ATTR treatments; prior TTR stabilizers were permitted after washout.
- Serum TTR protein was measured by validated enzyme-linked immunosorbent assay at baseline and weeks 1, 2, and 4; analyses were descriptive, comparing baseline with day 28 as mean percentage change and range. Preclinical work included primary human hepatocytes, transgenic mice, and cynomolgus monkeys.
Limitations
- The paper states that the study involves a very small number of patients with limited follow-up to date, and that continued serial measurements are planned to confirm durability. It also states that these are interim results from the first two dose groups in an ongoing dose-escalation study.
- Evident from the text: the clinical portion is open-label with no control group, uses descriptive analyses only, reports safety and pharmacodynamic effects through day 28, and does not report clinical outcomes such as disease progression, quality of life, or mortality.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
7 Valid · 1 Not valid · 5 Not checked · 56 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“TTR, which has a normal physiological role in vitamin A transport. 31”
What the sources say
- Supportedcites [31] 31. Müller ML, Butler J, Heidecker B. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Eur J Heart Fail 2020; 22: 39-53. source
The Introduction states that TTR physiologically transports retinol-binding protein. The Therapeutic antisense oligonucleotides section links this function to vitamin A levels, supporting the paraphrase that TTR normally plays a role in vitamin A transport. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“but are limited by the requirement for long-term administration to maintain TTR knockdown.”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Trial Design and Regimens section reports patisiran infusions every three weeks for 18 months, and Pharmacodynamics reports sustained TTR reduction during that period. The paper does not establish that long-term administration is required to maintain knockdown after treatment stops, or that this limitation applies to current ATTR treatments generally. (LLM, conf=0.82)
- Not checked — no full text of the sourcecites [13] 13. Adams D, Polydefkis M, GonzálezDuarte A, et al. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an openlabel extension study. Lancet Neurol 2021; 20: 49-59. source
- Partly supportedcites [14] 14. Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431-43. sourceExperimental — accuracy not yet measured
The Methods (Study Design and Treatment; page unavailable) report patisiran infusions every three weeks for 18 months, and the introductory passage describes its reduction of TTR protein. The paper does not establish that long-term administration is required to maintain TTR knockdown or characterize that requirement as a limitation of current ATTR treatments generally. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“More extensive TTR knockdown is associated with greater improvement in neuropathic end points in patients with hATTR polyneuropathy. 12”
What the sources say
- Partly supportedcites [12] 12. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11-21. sourceExperimental — accuracy not yet measured
The Primary End Point section reports a correlation between the degree of TTR reduction and change in mNIS+7, a composite neuropathy measure, at 18 months. The paper reports improvements in other end points, but our copy does not link the extent of knockdown to improvement across those end points. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“circulating TTR is produced almost entirely (>99%) within the liver, 2”
What the sources say
- Partly supportedcites [2] 2. Gertz MA, Benson MD, Dyck PJ, et al. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 2015; 66: 2451-66. sourceExperimental — accuracy not yet measured
The section labeled “Diagnosis and Classification” says TTR is synthesized primarily in the liver, supporting the liver as its main source. It does not give the claimed >99% figure for circulating TTR. No page number is available in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Inotersen is associated with serious side effects, including glomerulonephritis and decreased platelet counts. 17”
What the sources say
- Supportedcites [17] 17. Gertz MA, Scheinberg M, Waddington-Cruz M, et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-medi- - ated amyloidosis. Expert Rev Clin Pharmacol 2019; 12: 701-11. source
The Safety and tolerability section (p. 9) reports decreased platelet counts and glomerulonephritis in patients receiving inotersen, including severe cases. The Regulatory affairs section (p. 9) states that the US approval carries a black box warning for increased risks of thrombocytopenia and glomerulonephritis. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
43 more claims · 1 with their cited sources checked
Create a free account to see all 69 claims and every source verdict.
- Probably not a substantial claim. 11
- It may state two separate claims as one. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“which has already lead to investigational new drugs in clinical trials (NCT04601051)”
From Off-target effects in CRISPR/Cas9 gene editing (2023) · cites this paper as Gillmore et al., 2021
The cited source says what the claim attributes to it.
In the citing paper
“Ionizable lipid nanoparticles (LNPs) are a promising non-viral delivery platform for mRNA nanomedicines (13, 14) that have been used to deliver siRNA and CRISPR-based gene editing therapies to the liver in postnatal mouse, non-human primate, and clinical studies with encouraging results (15–18).”
From Ionizable Lipid Nanoparticles for Therapeutic Base Editing of Congenital Brain Disease (2023) · cites this paper as [17]
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805689 · Cited by 2,857
Bae, S., Park, J., & Kim, J.-S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu048 · Cited by 2,339
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
Tsai, S. Q., Zheng, Z., Nguyen, N. T., Liebers, M., Topkar, V. V., Thapar, V., Wyvekens, N., Khayter, C., Iafrate, A. J., Le, L. P., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3117 · Cited by 2,268
Li, H., Yang, Y., Hong, W., Huang, M., Wu, M., & Zhao, X. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0089-y · Cited by 1,715
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
Akinc, A., Maier, M. A., Manoharan, M., Fitzgerald, K., Jayaraman, M., Barros, S., Ansell, S., Du, X., Hope, M. J., Madden, T. D., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0591-y · Cited by 1,636
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Planté-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716793 · Cited by 1,452
Self-citationCRISPR–Cas9 genome editing induces a p53-mediated DNA damage response
Haapaniemi, E., Botla, S., Persson, J., Schmierer, B., & Taipale, J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0049-z · Cited by 1,264
Cited by
Items 1,601–1,700 of 1,725
Advancing hepatocyte-based therapies: A translational perspective
Sun, Z. X., Zhang, L., & Hui, L. (2026) · Cell stem cell · doi:10.1016/j.stem.2026.04.007 · Cited by 1
Expanding the Microbial Genomic Landscape and Biotechnological Applications of CRISPR-Cas Systems
Singh, S., Tiwari, H., Singh, M., Gautam, V., Gautam, A., & Gautam, H. K. (2026) · Biology · doi:10.3390/biology15100748 · Cited by 2
Chhabada, Y., & Yadav, K. S. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2671280 · Cited by 1
Li, L., Wang, M., Ye, X., Liu, Z., Duan, Y., Chen, X., Ouyang, Y., Wu, Q., Sun, M., & Xie, T. (2026) · MedComm · doi:10.1002/mco2.70700 · Cited by 4
Singh, A., Kumar, R., Chauhan, P., Mallikarjuna, M., Thaker, R., & Sambhav, K. (2026) · Cureus · doi:10.7759/cureus.108691 · Cited by 2
“Prolonged ex vivo culture conditions required for editing and expansion may further compromise stem cell fitness, leading to partial loss of stemness or altered differentiation potential, representing an important translational challenge for therapeutic HSC editing strategies [9].”
InfluentialProgress and challenges in cystic fibrosis gene editing
Witten, J. J., Egan, M. E., & Cereseto, A. (2026) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2026.04.007 · Cited by 1
Synthetic Biology Patents and Technology
Tiwari, I. M., Badgotya, B., Pawar, J., & Kiran, K. (2026) · Springer eBooks · doi:10.1007/978-981-95-3957-4_45
Advances in RNA-Based Therapeutics in Oncology
Lopes-Cardoso, H., Panão-Costa, J., Amaral, A. T., Soares-Gonçalves, J., Neves, B. F., Voronovska, A., Batista, A., Biscaia-Caleiras, M., Fonseca, N. A., Simões, S., et al. (2026) · Springer handbooks · doi:10.1007/978-3-032-01636-2_19
Self-citationA Primer on Rare Cardiac Diseases
Silva, E., Birnie, D. H., & Paterson, D. I. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.02.037
Liu, B., Klatt, D., Harris, C. E., McGuinness, M. K., Brendel, C., & Williams, D. A. (2026) · Nucleic Acids Research · doi:10.1093/nar/gkag500
Kana, S. L., & Leivant, M. (2026) · Springer eBooks · doi:10.1007/978-3-031-90919-1_6-1
CRISPR-Cas9 in Rare Genetic Disease Treatment: Mechanisms, Applications, and Future Perspectives
Sharma, A. (2026) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-35711
Rare disease preparedness: the time is now
Baynam, G. S., Draghia‐Akli, R., Pariser, A., et al. (2026) · Rare Disease and Orphan Drugs Journal · doi:10.20517/rdodj.2025.39
Transthyretin cardiomyopathy – diagnosis and therapeutic options
Pawlus, A., Kolebacz, K., & Średniawa, B. (2026) · Annales Academiae Medicae Silesiensis · doi:10.18794/aams/220040
“While tafamidis has the strongest evidence base (ATTR-ACT trial), analysis has shown that its benefits are significantly lower in patients in NYHA class III [5,24].”
Emdin, M. (2026) · CINECA IRIS Institutional Research Information System (Sant'Anna School of Advanced Studies)
An, J., Bai, J., Li, L., Xinsai, L., Zhang, Y., & Lv, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08389-3 · Cited by 1
“Although no CRISPR-based therapies for skeletal disorders have yet entered clinical trials, rapid advances in gene editing for hematologic and liver diseases suggest that future applications in bone metabolic disorders may become achievable [202, 203].”
Fayyaz, H. A., Noordhof, R. I., Fitriana, M., & Salvati, A. L. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103340
Park, J. J., Kuo, G., Khandekar, A., Shin, S., Wang, L., Taneja, T., & Mao, X. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33623-2.00012-x
Zeng, Y., Song, T., Liu, S., Liao, X., Hu, M., Yang, H., He, S., & Song, X. (2026) · Chinese Medical Journal BioMed · doi:10.65457/cmjbm-2026-0005 · Cited by 2
CRISPRessoSea: streamlined analysis and comparison of pooled amplicon CRISPR screens
Coleman, S., Tye, J., Furniss, D., Sainsbury, R., Rastogi, A., Xi, X., Murnyák, B., Bell, J., Skeate, J. G., Wang, M., et al. (2026) · BMC Bioinformatics · doi:10.1186/s12859-026-06518-9
The bench-to-bedside journey of circular RNAs in cancer: Status, challenges and future prospects
Lin, H., Tu, Y., Wang, P., Wang, T., & Long, F. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189639 · Cited by 1
Álvarez, M., Álamo, J. V. D., Richard, E., & Desviat, L. R. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102990
Travers, P. M., Wang, Y., Yan, Y., Zou, J., Halder, N., Clift, K. E., Cai, X., Kruse, R. L., Kumbhari, V., Ji, B., et al. (2026) · Livers · doi:10.3390/livers6040055
“…studies of systemic CRISPR-Cas9 editing underscore both the promise of these therapies and the persistent uncertainty surrounding off-target and long-term effects in the human liver, highlighting the current gap between animal models and human biology that might be addressed by EVLP platforms [45].”
Eskandani, N. A., Mirzaee, D., Farani, M. R., Hatami, A., Hatami, M., Ghasemzaei, M., Ghoreishian, S. M., Hwang, S.-K., & Huh, Y. S. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115921 · Cited by 2
Cancer and targeted drug delivery: Biotechnology-driven approaches for major cancers
Swamy, M., Puranik, H. H., Sorate, T., Awate, S. S., Doke, R. R., & Vinchurkar, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40620-1.00010-8
Technological advances in oncotherapeutics
Srivastav, S., Chaurasia, R., Bansal, H., Santoshi, S., Kumar, J., & Chourasia, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44181-3.00006-0
Khanna, K., Maki, M. A. M. A., Karwasra, R., Sharma, I., Bahere, M. H., Tayyab, S., Sharma, N., Rajagopal, M. S., Goel, B., & Raza, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43846-2.00021-0
Precision gene editing: From proof-of-concept to curative therapies
Cui, T., Li, B., Cai, B., Wang, H., & Li, W. (2026) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2026.06.004 · Cited by 1
Nanoengineering Systems for Gene Therapy: Mechanisms, Modalities, and Future Directions
Mais, R., Kumar, A., Ahmetaj, A. A., Burgos-Crespo, G., Sanchez, M. M., Roxas, D., Dcosta, C., Ilyas, A., Hadjiargyrou, M., & Zanganeh, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135988 · Cited by 1
“Among current nonviral systems, ionizable LNPs have the strongest clinical position because they support reproducible mixing, high nucleic-acid loading, and transient expression [17,70].”
A non-viral path to efficient and safe prime editing in vivo
Han, Y., & Kim, S. (2026) · Nature Nanotechnology · doi:10.1038/s41565-026-02205-1
CRISPRing through time: How cutting-edge technology is revolutionizing life sciences and medicine
Banik, I., & Coppé, J. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103003
“113 It is a single-dose intravenous infusion intended to edit TTR in hepatocytes, leading to a reduction in wild-type and mutant TTR protein.”
In vivo immune cell engineering from bench to clinical reality
Yu, H., Han, M., Zhao, X., Tang, C., Jia, Y., Jing, W., & Jiang, X. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100131
“Due to their excellent biocompatibility [92], tunable size and surface characteristics [93], and ability to efficiently deliver mRNA [94], siRNA [95], and genetic cargos or genome-editing tools to target cells [96], LNPs play a crucial role in in vivo immune cell engineering.”
Hou, Z.-T., Jia-rui, C., Fang, G.-X., & Yang, G. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118228
Translational Nanomedicine and Delivery Tools for Cardiovascular Disease Therapy and Diagnostics
Miller, M. A., & Williams, R. M. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-22285-5_10
Xu, B., Yang, H., Chen, K. X., Wang, L., Fan, J., 杜垬, Guo, W., Ruan, R. R., Yan, X., Yin, Y., et al. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108979
Context-Aware Dual-Graph Neural Network for Cellular State Inference Under Genetic Perturbations
Cai, L., Yu, J., Liu, L., Lin, Q., Li, X., & Wong, K. (2026) · IEEE Transactions on Big Data · doi:10.1109/tbdata.2026.3712210
“Studies of the transcriptome also support precise cellular engineering [6], [7], [8], [9], [10], [11].”
The landscape and trajectory of global CRISPR therapeutics
Şahin, C., Formica, T. M., Silva, A., Pelle, G. D., Davis, M. C., Andersen, D. G., Çavdar, M., Santos, L., Qiu, L., Olsen, A. L., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103011 · Cited by 1
Allegro, V., Sinagra, G., & Merlo, M. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag200
Hosseinpour-Moghadam, R., Sadrai, S., & Toliyat, T. (2026) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2026.2686958
Badru, M. D., Ghansah, V., Adesanya, I. O., et al. (2026) · Australian Journal of Biomedical Research · doi:10.63946/aubiomed/18967
Ide, T., Yoshikawa, M., & Koike, H. (2026) · Neurology and Therapy · doi:10.1007/s40120-026-00994-0
“Emerging strategies, including CRISPR-based gene editing such as NTLA-2001, offer the possibility of durable, potentially one-time therapy with profound and sustained TTR reduction [23, 49].”
InfluentialZaman, W., & Ayaz, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146467
“Clinically validated LNP delivery of Cas9 mRNA and guide RNA has produced substantial hepatic target reduction in patients [136], but the permanent genomic outcome in that study under-scores the distinction between transient payload exposure and reversible therapeutic action.”
Molecular Engineering of CRISPR Nanomaterials toward Cancer Theranostics
Li, G., Wang, S., & Zhang, J. (2026) · ACS Nano Medicine · doi:10.1021/acsnanomed.6c00121
Offering Prenatal Testing for Adult-Onset Diseases (Argument AGAINST)
Grody, W. W. (2026) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000001046
Dang, T., Roman, A., Zimmer, A., Lebedin, M. Y., Bahry, E., Grifol, C. M., Esser, M., Sevim-Wunderlich, S., Miller, D. C., Diecke, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.24.740048
Kim, N., Huang, Z., Born, M., & Camperi, J. (2026) · Cells · doi:10.3390/cells15151333
“Delivery of the nuclease via mRNA provides an additional transient expression modality, avoiding the risks of random genomic integration associated with DNA vectors [83].”
Abhijeet Patnaik, S. V. (2026) · International Journal of Biosciences (IJB) · doi:10.12692/ijb/28.6.216-272
Niazi, S. K. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080941
“…designated NTLA-2001, leveraged the potential of a single administration of gene editing and the hepatic tropism of intravenously administered LNPs. Notably, it resulted in an average 87% reduction in serum transthyretin levels in the high-dose arm four weeks after a single treatment [147].”
Beyond the parasite: reframing cutaneous leishmaniasis as a host-microbiome-vector ecosystem
Huët, M. A. L., & Bhaw‐Luximon, A. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127250
Pooley, J. R., Bienemann, A. S., Young, A., Hollings, O., Wu, J., Mayo, E., Chu, C. J., & Singleton, W. (2026) · Fluids and Barriers of the CNS · doi:10.1186/s12987-026-00831-4 · Cited by 1
“Application of CRISPR to novel therapeutics has been delayed by concerns about off-target mutation potential but with the conclusions of this article now under intense challenge current clinical trial data are awaited with optimism [74].”
Nonhuman Primate Genomes Have Limited Relevance for Evaluating Human CRISPR Off-Target Effects
Blaha, L. C., Bosinger, M., Bodian, D. L., Qu, V., Warner, J. B., Borges, C. M., & Mueller, C. (2026) · Human Gene Therapy · doi:10.1177/10430342261466427
Glomerulosclerosis in 2026: From Pathophysiological Mechanisms to Precision Therapeutics
Kim, J. Y., & Lee, J. Y. (2026) · Sclerosis · doi:10.3390/sclerosis4030023 · Cited by 1
Ahad, A., Hullon, D., Singh, T., Dabiry, S. M., Sakthivel, L., Padaria, J., Rekhraj, A. S., & Bhattacharjee, A. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10170-3
“Editing those nodes, rather than isolated genes, could yield broader therapeutic durability.”
Ali, H., Farooq, M., Shah, U., Khan, B., & Malik, S. (2026) · Pharmacophore · doi:10.51847/4ylxcn8kfc
Zhang, Y., Yang, Y., Liu, Z., Li, Y., Xue, Y., Zhang, Z., Chen, G., Liu, J., He, M., Lu, T., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.08.006 · Cited by 2
Li, O. M., Li, Y., & Li, S. X. T. (2026) · Cureus · doi:10.7759/cureus.114354
“…TTR in hereditary transthyretin amyloidosis, produced dose-dependent and sustained reductions in circulating transthyretin after a single infusion [34], and the same delivery platform was extended to KLKB1 in hereditary angioedema, where a single dose durably reduced attack frequency [35].”
Non-invasive nanoparticle barcoding in nonhuman primates
Jang, B., Zenhausern, R., Lian, L., Gentry, K., Abbas, A. M., Rudden, S., Shin, Y.-J., Doan, J., Loughrey, D., Curran, E. H., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03262-6 · Cited by 1
Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics
Athanasopoulou, K., Daneva, G. N., Michalopoulou, V.-I., Stamelou, M.-L., Tsiakanikas, P., & Adamopoulos, P. G. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48080809
“A trial (NCT04601051) recently demonstrated the safety and efficacy of LNP-mediated delivery of a CRISPR/Cas9 system for the in vivo knockout of the TTR gene in patients with hATTR [236].”
Rathore, S., Gupta, A., Shah, K., Chauhan, N. S., & Gupta, S. (2026) · Ageing Research Reviews · doi:10.1016/j.arr.2026.103301 · Cited by 2
Targeted delivery of mRNA to immune cells for in vivo cell therapy
Wang, D., Li, Y., Deng, J., Li, M., & Wu, L. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2716510
“For genetic disorders, the transient peak of mRNA-encoded editors minimises the window for off-target effects, offering a safer alternative to prolonged expression mediated by viral vectors for precision genome editing (Gillmore et al. 2021).”
Palabıyık, E. (2026) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-026-01033-8 · Cited by 1
Gene therapy: The current trajectory of clinical and commercial translation
Gibson, J. R., & Cottle, R. N. (2026) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2026.08.002
On-target and off-target activities of CRISPR therapeutics across scales
Magdy, M., Gibson, J. R., Dhungana, A., Herring‐Nicholas, A., Cottle, R. N., & Josephs, E. A. (2026) · Trends in biotechnology · doi:10.1016/j.tibtech.2026.07.015 · Cited by 1
Mody, H. R., Narula, J., Shastri, P. N., Miles, D., Liu, Y., Shivva, V., Raghav, J. G., Roth, G. A., Gupta, A., Habtemariam, B. A., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01267-2
“…systems, and DNA) and type of the non-viral vector used i.e., liposomes, lipid nanoparticle (LNP) based, or physical methods such as electroporation, and chemically modified nucleic acid conjugates i.e., silencing RNA, small interfering RNA (siRNA), and antisense oligonucleotides (ASOs) (3, 6, 7).”
Chun, S., Nam, H., Lee, D., Lee, Y., Park, C. H., Lim, C., Kim, D., Park, J. S., Kim, K.-P., Choi, H. S., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c13674
Rezaee, M., Izadi, F., Nobaharian, S., Hassani, L., Rezaei, E., Amini, S. S., Pourfathollah, A. A., Kowsari, A., Naeimi, S., Varnamkhasti, K. K., et al. (2026) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-026-00824-0
“As a researcher’s selection guide, if the target tissue is liver and the cargo is mRNA or RNP, the recommended vehicle is LNP (SORT-enabled) due to highest efficiency, scalability, and clinical validation [28, [65, 66].”
InfluentialLongmire, J., Smith-Jaoudi, H., Balar, E., & Romeo, H. (2026) · Georgetown Medical Review · doi:10.52504/001c.166340
RNA delivery to the corneal endothelium using charge-altering releasable transporters
Wang, S. K., Li, Z., Shah, S. H., Edwards, Q. A., Bouffard, R., Hines, E. S., Imventarza, J. A., Korte, S., Lawrence, M. S., Song, E., et al. (2026) · Science Advances · doi:10.1126/sciadv.ady8161
“Together, these technologies made possible the development of mRNA vaccines against coronavirus disease 2019 (COVID-19) ( 12 , 13 ) and are now being adapted for protein replacement therapies ( 14 , 15 ), gene editing approaches ( 16 , 17 ), and personalized cancer treatments ( 18 , 19 ).”
Sanjeyan, N., Gobika, G., Harshini Reethu, S., & Renuka, A. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20262885
Chandrasekaran, S., Duraisamy, N., Jagadeesan, M., Palukuri, Y. K., & Selvan, S. T. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103007
Madsen, A., Selfjord, N., Martínez-Lage, M., Loyd, A.-L., Kurgan, G., Stahlberg, M., Lindgren, J., Touza, J. L., Wigge, L., Firth, M. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-77144-5 · Cited by 3
du Rand, A., Masterson, C., Verdon, D. J., Siow, A., Loef, E. J., Dunbar, P. R., Kingston, R. L., Harris, P. W. R., & Sheppard, H. M. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70172
“8,9 Physical delivery methods, namely electroporation, have dominated the ex vivo CRISPR/Cas landscape for preclinical gene therapy studies 10 and clinical trials, 11 owing to their efficient nuclear delivery capacity.”
Swaroopa, M. M., Regulapati, M., Sruthi, G. K., Nalluri, R., Royyuru, L. S. T., Ahalya, M., Kejiya, C., Hema sri priya, J., Siri, K., Sri Lakshmi Janani, A., et al. (2026) · Advances in computational intelligence and robotics book series · doi:10.4018/979-8-2600-0161-5.ch005
Mahdy, A., ElBakry, O. M., Eladl, O., Etman, A. E., Attia, Y. A. M., Abdallah, A. K., Abdelmalek, M. A., Helal, M. W., Hamdy, M., El-Sayyad, G. S., et al. (2026) · Nanotechnology · doi:10.1088/1361-6528/ae9bcd · Cited by 3
“Key regulatory questions include whether these systems should be classified primarily as advanced medicinal products, gene therapies, biologics, or combination products, as regulatory pathways may differ depending on the delivery platform and mechanism of action [130].”
Hu, B., Gutty, V. S. R., Herzog, R. W., & Duan, D. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1930231
“In 2021, Gillmore et al. provided the first demonstration of the safety and efficacy of intravenously delivered CRISPR-Cas9 therapy for another rare hereditary disease, transthyretin amyloidosis (ATTR) (NCT04601051) (9).”
Yang, Y., Song, T., Huang, K., Huang, H., Zhao, M., & Li, Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18091094
“Nevertheless, clinical translation requires long-term follow-up for potential off-target editing, immune activation, infusion reactions, liver toxicity, and durability of therapeutic benefit [3,11,46,50].”
Srivastava, R. A. K. (2026) · Cells · doi:10.3390/cells15171575
“However, LDLR-dependent strategies have intrinsic limitations in patients with severe HeFH and especially HoFH, where LDLR function is absent or severely impaired [18,165,194,195].”
Liu, X., Zhu, M., Zou, C., Cao, Z., Wang, Y., Yang, G., Liu, X., Wu, Y., Yu, D., Zheng, D., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103018
“47,48 Our present study clearly demonstrates that LNP-ZPIB exhibits potent antitumor activity in both multiple glioma mouse models and a patient-derived human-ized-NKG model.”
Cas12a chRDNA-mediated in vivo genome editing for high specificity functional gene disruption
Losa, M., Rajmane, P., Stanaway, M., Coons, M., Munoz, A., Garish, V., Tan, B., Thompson, M., Gonzalez, R., Churchward, G., et al. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.103084 · Cited by 1
“Heavily end-and inter-nally-modified all-RNA sgRNAs, as used by Finn et al. and in NTLA-2001, differ from the chRDNAs used in this study, which combine DNA substitutions throughout the spacer with terminal chemical modifications and confer exonuclease resistance 52 and reduced biochemical off-target editing.”
InfluentialPrecision genome editing strategies for enduring lipid lowering in atherosclerosis
Chowdhury, D., Singh, N., Garai, S., Pandey, D. P., & Bodakhe, S. H. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179312
Kaur, K., Chandel, S., & Singh, R. (2026) · Next Nanotechnology · doi:10.1016/j.nxnano.2026.100741
Programmable enzymes for targeted gene insertion
Lampe, G. D., King, R. T., & Sternberg, S. H. (2026) · Nature Reviews Genetics · doi:10.1038/s41576-026-01002-9
Polat, M., Dinçer, S. A., & Terzi, Y. K. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1017730
Ikrar, T., Muchsin, W., & Sophian, A. (2026) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.70143
Gene therapies (2015–2025): determinants of translational success
Sackett, J., Jaber, S., Gangapur, P., Biernat, M., & Bao, S. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118450
Abbasi, S., Bockley, K. M., Dohr, J., Chen, E., Carter, D. M., Berlinicke, C. A., Lian, X., Viskadourou, M., Burke, E. V., Ensign, L. M., et al. (2026) · ACS Nano · doi:10.1021/acsnano.6c10855
Advancements in CRISPR-based in vivo gene therapy for hemophilia
Zhang, X., Xu, K., Zou, S., Zhu, Z., Teng, S., & Huang, P. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1924733
“In a clinical trial using LNPs to encapsulate Cas9 mRNA and sgRNA for the treatment of transthyretin amyloidosis (Gillmore et al., 2021), almost no adverse events occurred, validating the safety of LNPs in human applications.”
Clinical translation of CRISPR-Cas9 therapeutics in cancer and inherited genetic disorders
Bashir, K., Vasudev, P., Chhetri, V., Dubhashi, D. P., Teli, Y. G., Biswas, R., Ramaiah, S., & Anbarasu, A. (2026) · Frontiers in Genome Editing · doi:10.3389/fgeed.2026.1868779
Beyond Precision: A Multidimensional Framework for Selecting Genetic Medicine Platforms
Wieland, J., Jackson, P., Penrod, W., Nadauld, S., & Barrott, J. J. (2026) · Cells · doi:10.3390/cells15181647
“In genome editing, therapeutic intervention occurs directly within disease-relevant genes or regulatory elements that control disease biology [1–4, 10, Recent technological advances have extended genome engineering beyond conventional double-strand-break-mediated editing [23–29 ,49– 71].”
InfluentialLei, X., Chen, D., Zhang, K., Liu, X., Chen, Q., Zhang, Y., Ji, R., Zhu, J., Zhang, Q., Zhang, Y., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01787-4 · Cited by 1
Hani, U. E., Sulaiman, M., Zafar, H., & Raza, F. (2026) · Journal of Materials Chemistry B · doi:10.1039/d6tb01950a · Cited by 1
AL-Khfaji, K. M. S., AL-MOUSAWY, J. M., Al-Juhaishi, A. M. R., Khadim, F. T., Jasim, G. N., & Radhi, F. A. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108942
The myth of Sisyphos and the route of cardiovascular medicine
Lüscher, T. F. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag586 · Cited by 1
Gene therapy for rare diseases: technological innovation and clinical translation
ZHANG, Y.-J., & Yuan, H. (2026) · Shengming kexue · doi:10.3724/cbls.2026132
Deng, Z., Dunn, A. W., Sun, D. Q., & Shi, D. (2026) · Applied Physics Reviews · doi:10.1063/5.0342617 · Cited by 1
Multifunctional nucleic acid-based therapy in fibrosis-related diseases
Cheng, J., Zhou, M., Guo, Y., Yang, Y., Lv, W., Renzeng, Y. A. N. G., Xie, Y., Jiang, Y., Yao, L., Qi, C., et al. (2026) · Science China Chemistry · doi:10.1007/s11426-025-3231-6
Genetics of Inflammatory Bowel Disease—What is Unsought Goes Undetected
O’Donnell, J. E. M., Zeef, D. H., Gopan, A., & Muise, A. M. (2026) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2026.05.016
Chemically modified CRISPR enzymes for multi-organ genome editing in vivoPreprint
Baehr, C. M., Ressnerova, A., Kang, M. H., Zhao, S., Le, B., Haddad, R. F., Asija, K., Damante, M. A., Sharma, R. K., George, C. A., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.14.751351
Metadata
- Authors
- Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., Phillips, J., Xu, Y., Amaral, A., Boyd, A. P., Cehelsky, J. E., McKee, M. D., Schiermeier, A., Harari, O., Murphy, A., Kyratsous, C. A., Zambrowicz, B., Soltys, R., Gutstein, D. E., Leonard, J., Sepp-Lorenzino, L., & Lebwohl, D.
- Affiliations
- University of Auckland (NZ)
- From the National Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital (J.D.G., M.F.) and Richmond Pharmacology, St. George’s University of London (J.T.) — both in London; New Zealand Clinical Research (E.G.), University of Auckland (E.G.), and the Department of Neurology, Auckland City Hospital (J.K.) — all in Auckland, New Zealand; Intellia Therapeutics, Cambridge, MA (M.L.M., J.S., D.O., K.R.W., K.W., J.P., Y.X., A.A., A.P.B., J.E.C., M.D.M., A.S., J.L., L.S.-L., D.L.); and Regeneron Pharmaceuticals, Tarrytown, NY (O.H., A.M., C.A.K., B.Z., R.S., D.E.G.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 493-502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177445623
- Cited by
- 1,801
- References
- 35
- Citations by year
- 2026: 349 · 2025: 332 · 2024: 368 · 2023: 336 · 2022: 328 · 2021: 84
- FWCI
- 228.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Regeneron Pharmaceuticals
- Intellia Therapeutics
- Topics
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- transthyretin amyloidosis, hereditary ATTR amyloidosis, CRISPR/Cas9 genome editing, in vivo gene therapy, prealbumin, polyneuropathy, single ascending dose, pharmacodynamics, safety
- MeSH terms
- Gene Editing, RNA, Guide, CRISPR-Cas Systems, Female, Humans, Infusions, Intravenous, Liposomes, Male, Middle Aged, Prealbumin, RNA, Messenger, RNA, Guide, Kinetoplastida, Gene Transfer Techniques, Amyloid Neuropathies, Familial, Nanoparticles, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27, under version 3 of the claim definition (prompt extract-v3).
A second model labelled each claim on 2026-09-27 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.



